TAR DNA-binding protein 43

ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Proteins, Biology, Amyloidosis, Neurological disorders, Structural proteins, Alzheimer's disease, Amyloid, Histopathology, TAR DNA-binding protein 43, Neurodegeneration, Promis

TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimers Association International Conference (AAIC) to be held July 26-30, 2021 in Denver, USA and online.

Key Points: 
  • TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimers Association International Conference (AAIC) to be held July 26-30, 2021 in Denver, USA and online.
  • ProMIS Chief Scientific Officer, Dr. Neil Cashman will give an oral presentation entitled: Selective targeting of intracellular misfolded, pathogenic TDP-43 with rationally designed intrabodies.
  • Dr. Johanne Kaplan, ProMIS Chief Development Officer, will present the poster entitled: Conformational epitopes exposed on misfolded toxic forms of amyloid-beta, tau and alpha-synuclein directly contribute to their seeding activity.
  • Both presentations will be available on the ProMIS website ( www.promisneurosciences.com ) after the AAIC closes on July 30.

Discovery of the role of a key gene in the development of ALS

Retrieved on: 
Wednesday, June 30, 2021
Branches of biology, Biology, Neurological disorders, C9orf72, Amyotrophic lateral sclerosis, TAR DNA-binding protein 43, Mutation, Genetics of amyotrophic lateral sclerosis, UBQLN2

The loss of function of an important gene, C9orf72, may affect communication between motor neurons and muscles in people with this disease.

Key Points: 
  • The loss of function of an important gene, C9orf72, may affect communication between motor neurons and muscles in people with this disease.
  • A mutation in the C9orf72 gene is the primary genetic cause of ALS.
  • The study showed the effect of the loss of function induced by the mutation of the C9orf72 gene on communication between motor neurons and muscles.
  • The research group also revealed the gene's role on the protein TDP-43 (transactive response DNA binding protein 43) which plays an important role in ALS.

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

Retrieved on: 
Wednesday, February 24, 2021
Branches of biology, Neurological disorders, Biology, Life sciences, Neurodegeneration, Neuroscience, Senescence, Eli Lilly and Company, TAR DNA-binding protein 43

The presentations will highlight preclinical results from the Companys wholly-owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TAR DNA-binding protein 43 (TDP-43) for neurodegenerative diseases.

Key Points: 
  • The presentations will highlight preclinical results from the Companys wholly-owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TAR DNA-binding protein 43 (TDP-43) for neurodegenerative diseases.
  • The presentations will showcase how AC Immunes expertise in discovery, assay development and characterization of promising candidates powers its industry-leading pipeline.
  • AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases.
  • It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.